Patent ID: 6579868
Filing Date: 2003-06-17
Classification: A61K,A61P,C07D

Abstract:
A purine compound represented by the formula (I), or its pharmacologically acceptable salt thereof, wherein in the formula (I),R1 represents: 1) formula: â€ƒwherein X is a hydrogen atom, a hydroxyl group, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted acyl group, an optionally substituted acyloxy group or an optionally substituted amino group; and R5 and R6 are the same as or different from each other and each represents a hydrogen atom, an optionally substituted lower alkyl group, an optionally substituted saturated or unsaturated C3-8 cycloalkyl group, an optionally substituted C3-8 cycloalkyl-C2-6 alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally protected carboxyl group or an optionally substituted four- to six-membered ring having at least one hetero atom; optionally R5 and R6 is either an oxygen atom or a sulfur atom together, or R5 and R6 are a ring which may have a hetero atom being formed together with a carbon atom to which they are bonded; wherein said ring may be substituted; or 2) a five- or six-membered aromatic ring that may have a substituent group and a hetero atom; W represents formula â€”CH2CH2â€”, â€”CH&boxH;CHâ€” or â€”Câ‰¡Câ€”; R2 represents a hydrogen atom, an optionally substituted lower alkyl group, a hydroxyl group or a formula â€”NR7R8, wherein R7 and R8 are the same as or different from each other and each represents a hydrogen atom, a hydroxyl group, an optionally substituted lower alkyl group, an optionally substituted acyl group, an optionally substituted C3-8 cycloalkyl group, an optionally substituted aryl group or an optionally substituted heteroaryl group; optionally R7 and R8 are a saturated ring which is formed together with a nitrogen atom to which they are bonded, said saturated ring is selected from the group consisting of aziridine, azetidine, pyrrolidine, piperidine, perhydroazepine, perhydroazocine, piperazine, homopiperazine, morpholine and thiomorpholine; wherein the ring optionally has a substituent selected from the group consisting of a lower alkyl group, a halogen and an acyl group; R3 represents an optionally substituted C3-8 cycloalkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group or an optionally substituted C2-6 alkenyl group; and R4 represents a hydrogen atom, an optionally substituted lower alkyl group, an optionally substituted C3-8 cycloalkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted C2-6 alkenyl group, an optionally substituted C2-6 alkynyl group or an optionally substituted cyclic ether group; wherein when W is â€”CH2CH2â€”, then X is not a hydrogen atom or an alkyl group.